Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Candel Therapeutics (Nasdaq: CADL) announced on May 1, 2026 that its Compensation Committee granted inducement stock options on April 30, 2026 to two new employees for an aggregate of 29,400 shares at a per‑share exercise price of $6.18.

The options were granted under the company’s 2025 Inducement Plan (adopted December 24, 2025) and vest 25% after one year of service, with the remaining 75% vesting in 36 equal monthly installments, subject to continued employment. Grants were made in accordance with Nasdaq Listing Rule 5635(c)(4).

News Market Reaction – CADL

+16.38%

+16.38% Session close to close

In the May 4 session, CADL gained 16.38%, reflecting a significant positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock surged +16.4% in the session following this news. A strong positive reaction aligns with C...

Analysis

The stock surged +16.4% in the session following this news. A strong positive reaction aligns with CADL’s position above its 200-day MA and proximity to its 52-week high, but would likely reflect sentiment beyond this routine inducement grant. Historically, larger moves followed clinical or financial milestones rather than standard equity compensation. Investors have also faced potential dilution capacity under a $300,000,000 shelf, so sustained gains have depended on continued clinical progress and disciplined use of financing tools.

Key Figures

Inducement options: 29,400 shares Exercise price: $6.18 per share Initial vesting: 25% +5 more

8 metrics

Inducement options 29,400 shares Aggregate stock options granted to two new employees on April 30, 2026

Exercise price $6.18 per share Strike price of inducement stock options under 2025 Inducement Plan

Initial vesting 25% Vests on first anniversary of each employee’s start date

Subsequent vesting 75% over 36 months Remaining options vest in 36 equal monthly installments

Plan adoption date December 24, 2025 Board adoption date of the 2025 Inducement Plan

Current price $6.18 Price at time of context, flat over prior 24 hours

52-week range $4.3384 – $7.655 Pre‑news 52‑week low and high for CADL

Shelf capacity $300,000,000 Total securities capacity under Form S-3 shelf registration

Historical Context

5 past events · Latest: Apr 29 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Apr 29	Commercialization agreement	Positive	-0.3%	EVERSANA deal to support potential U.S. launch of CAN-2409 in prostate cancer.
Apr 02	Inducement grants	Neutral	+0.4%	Inducement stock options for new employees under 2025 Inducement Plan.
Mar 17	Clinical data update	Positive	+3.6%	Phase 2a NSCLC data showing 25.4‑month median OS and 50% 24‑month survival.
Mar 12	Earnings and pipeline	Positive	-2.4%	Q4 and FY25 results, financing updates, and plans for Phase 3 and BLA submission.
Mar 09	Clinical presentation	Positive	+3.9%	Announcement of Phase 3 prostate cancer data presentation at AUA 2026.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent news skewed toward positive clinical and corporate developments, with mixed price follow-through: some strong gains on clinical updates, but occasional selloffs or flat trading after seemingly positive items.

Recent Company History

Over the last several months, Candel reported multiple milestones: extended survival data in NSCLC (news_id 1027950), a planned pivotal Phase 3 NSCLC trial and BLA timing with cash runway into Q1 2028 (1026056), and additional prostate cancer data presentations (1024028). It also entered a commercialization agreement for CAN-2409 in localized prostate cancer (1047524) and previously announced similar inducement grants (1035500). Today’s Nasdaq Rule 5635(c)(4) inducement options fit that pattern of routine corporate updates rather than a major clinical or financing catalyst.

Key Terms

inducement stock options, nasdaq listing rule 5635(c)(4), exercise price, inducement plan

4 terms

inducement stock options financial

"the Compensation Committee ... granted to two new employees, stock options to purchase an aggregate"

Inducement stock options are grants of the company’s stock rights given to recruit or retain a specific executive or employee, often as a signing bonus instead of cash. Investors care because these awards can increase the total shares outstanding and dilute existing ownership, alter future reported expenses, and signal how the company is paying for talent; think of them as a hiring incentive paid in future company pieces rather than immediate money.

nasdaq listing rule 5635(c)(4) regulatory

"in accordance with Nasdaq Listing Rule 5635(c)(4) and were granted pursuant to the terms"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

exercise price financial

"stock options to purchase an aggregate of 29,400 shares ... with a per share exercise price of $6.18."

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

inducement plan financial

"The inducement stock options were made under the Company’s 2025 Inducement Plan (the Plan)"

An inducement plan is a program a company creates to encourage employees or new hires to stay or join by offering special benefits or rewards. It’s like a company giving extra bonuses or perks to persuade someone to choose their job over others, helping the company attract and keep talented workers.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NEEDHAM, Mass., May 01, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients with cancer, today announced that on April 30, 2026, the Compensation Committee of Candel’s Board of Directors (the Board) granted to two new employees, stock options to purchase an aggregate of 29,400 shares of the Company’s common stock, with a per share exercise price of $6.18.

The inducement stock options were made under the Company’s 2025 Inducement Plan (the Plan) and will vest with respect to 25% of the shares of common stock underlying the award on the first anniversary of the employee’s start date, and the remaining 75% of the shares of common stock underlying the inducement stock options will vest in 36 equal monthly installments thereafter. All vesting related to inducement awards is subject to the employees’ continuing service at the Company through the applicable vesting date.

The above-described awards were each granted as inducement material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4) and were granted pursuant to the terms of the Plan. The Plan was adopted by the Board on December 24, 2025.

About Candel Therapeutics

Candel is a clinical-stage biopharmaceutical company focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. Candel has established two clinical-stage multimodal biological immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) gene constructs, respectively. Aglatimagene besadenovec (CAN-2409 or aglatimagene) is the lead product candidate from the adenovirus platform. The Company recently completed successful phase 2a clinical trials of aglatimagene in non-small cell lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC), and a pivotal, placebo-controlled, phase 3 clinical trial of aglatimagene in localized prostate cancer, conducted under a Special Protocol Assessment agreed with the U.S. Food and Drug Administration (FDA). The FDA also granted Fast Track Designation, Regenerative Medicine Advanced Therapy Designation to aglatimagene for the treatment of newly diagnosed localized prostate cancer in patients with intermediate-to-high-risk disease, Fast Track Designation in NSCLC, and both Fast Track Designation and Orphan Drug Designation to aglatimagene for the treatment of PDAC.

Linoserpaturev (CAN-3110) is the lead product candidate from the HSV platform and is currently in an ongoing phase 1b clinical trial in recurrent high-grade glioma, evaluating the effects of repeat linoserpaturev injections. Initial results were published in Nature and Science Translational Medicine and linoserpaturev received Fast Track Designation and Orphan Drug Designation from the FDA. Finally, Candel’s enLIGHTEN™ Discovery Platform is a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors.

For more information about Candel, visit: www.candeltx.com

Investor Contact
Theodore Jenkins
Vice President, Investor Relations and Business Development
Candel Therapeutics, Inc.
tjenkins@candeltx.com

Media Contact
Ben Shannon
ICR Healthcare
CandelPR@icrhealthcare.com

FAQ

What did Candel Therapeutics (CADL) announce on May 1, 2026 about employee stock options?

Candel announced inducement option grants totaling 29,400 shares at a $6.18 exercise price. According to the company, the awards were granted April 30, 2026 under the 2025 Inducement Plan and tied to new hires under Nasdaq Rule 5635(c)(4).

What is the vesting schedule for the CADL inducement stock options granted April 30, 2026?

The options vest 25% after one year, then the remaining 75% vest in 36 equal monthly installments. According to the company, all vesting is conditioned on the employees' continued service through each applicable vesting date.

Under which plan and Nasdaq rule were CADL stock options granted to new employees?

The inducement options were granted under the company’s 2025 Inducement Plan and in reliance on Nasdaq Listing Rule 5635(c)(4). According to the company, the Plan was adopted by the board on December 24, 2025.

How many employees received inducement grants and what is the aggregate size for CADL (May 2026)?

Two new employees received inducement grants totaling 29,400 shares in the aggregate. According to the company, the awards were issued April 30, 2026 as material inducements for hiring.

Will CADL's inducement option grants immediately impact outstanding shares or dilute existing shareholders?

The announcement reports option grants but does not state immediate share issuance or dilution figures. According to the company, options are exercisable at $6.18 per share and vest over time, with dilution dependent on future exercises.